InsidersTradesSigma
Follow the Tandem Diabetes Care, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was reported on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MARK NOVARA. Every trade is free.
Analysts rate Tandem Diabetes Care, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Tandem Diabetes Care, Inc. es una empresa centrada en el desarrollo de dispositivos médicos para el manejo de la diabetes. Se concentra en soluciones innovadoras para mejorar la calidad de vida de las personas con diabetes.